Cargando…

Solid formulation of a supersaturable self-microemulsifying drug delivery system for valsartan with improved dissolution and bioavailability

In order to improve the dissolution and oral bioavailability of valsartan (VST), and reduce the required volume for treatment, we previously formulated a supersaturable self-microemulsifying drug delivery system (SuSMEDDS) composed of VST (80 mg), Capmul(®) MCM (13.2 mg), Tween(®) 80 (59.2 mg), Tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeom, Dong Woo, Chae, Bo Ram, Kim, Jin Han, Chae, Jun Soo, Shin, Dong Jun, Kim, Chang Hyun, Kim, Sung Rae, Choi, Ji Ho, Song, Seh Hyon, Oh, Dongho, Sohn, Se Il, Choi, Young Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706875/
https://www.ncbi.nlm.nih.gov/pubmed/29212229
http://dx.doi.org/10.18632/oncotarget.21691
Descripción
Sumario:In order to improve the dissolution and oral bioavailability of valsartan (VST), and reduce the required volume for treatment, we previously formulated a supersaturable self-microemulsifying drug delivery system (SuSMEDDS) composed of VST (80 mg), Capmul(®) MCM (13.2 mg), Tween(®) 80 (59.2 mg), Transcutol(®) P (59.2 mg), and Poloxamer 407 (13.2 mg). In the present study, by using Florite(®) PS-10 (119.1 mg) and Vivapur(®) 105 (105.6 mg) as solid carriers, VST-loaded solidified SuSMEDDS (S-SuSMEDDS) granules were successfully developed, which possessed good flow properties and rapid drug dissolution. By introducing croscarmellose sodium (31 mg) as a superdisintegrant, S-SuSMEDDS tablets were also successfully formulated, which showed fast disintegration and high dissolution efficiency. Preparation of granules and tablets was successfully optimized using D-optimal mixture design and 3-level factorial design, respectively, resulting in percentage prediction errors of <10%. In pharmacokinetic studies in rats, the relative bioavailability of the optimized granules was 107% and 222% of values obtained for SuSMEDDS and Diovan(®) powder, respectively. Therefore, we conclude that novel S-SuSMEDDS formulations offer great potential for developing solid dosage forms of a liquefied formulation such as SuSMEDDS, while improving oral absorption of drugs with poor water solubility.